Skip to content

The American Consumer Institute

FacebooktwitterlinkedinrssvimeoFacebooktwitterlinkedinrssvimeo
Newsletter Sign Up ✉
VISIT : TheLostEconomy.com
  • Home
  • About Us
    • Experts
  • Blog
  • Issues
    • Technology
    • Consumer Tips / Health
    • Internet Public Policy Issues
    • ENERGY / Environment
    • Finance / Insurance
    • Taxation
  • News
  • Podcast
  • Events
  • Donate
  • Contact

ACI Files Comments with the FTC Regarding PBM Business Practices and their Impact on Drug Prices

Posted on April 20, 2022April 20, 2022 by Steve Pociask

The Federal Trade Commission is currently collecting public comments on the “Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers.” Today ACI filed its comments with the FTC. The comments are available here.

Further Reading

  • Pharmacy Benefit Managers Drive High Drug Prices
  • ACI Sends a Letter to Congress on Reducing Patient Drug Prices
  • Town Hall: Level the Playing Field for Drug Companies and Patients
  • Inside Sources: Biden Administration Should Continue Closing PBM Loopholes
  • The Hill: Rx Middlemen Cost American Consumers Billions Each Year
  • The Hill: Consumers agree that Greater transparency among PBMs is needed
FacebooktwitterredditlinkedinFacebooktwitterredditlinkedin
Posted in Consumer Tips / Health, Health, Issues, NewsTagged drug prices, FTC, PBMs, pharmacies

Post navigation

Pharmacy Benefit Managers Drive High Drug Prices
Can JetBlue’s Deal with Spirit Increase Competition and Consumer Benefits?

THE AMERICAN CONSUMER INSTITUTE

:

CENTER FOR CITIZEN RESEARCH · COPYRIGHT © 2022

Privacy Policy | Terms of Use
  • Home
  • About Us
    • Experts
  • Blog
  • Issues
    • Technology
    • Consumer Tips / Health
    • Internet Public Policy Issues
    • ENERGY / Environment
    • Finance / Insurance
    • Taxation
  • News
  • Podcast
  • Events
  • Donate
  • Contact